Successful Use of Golimumab in a Child with Juvenile Polyarthritis
https://doi.org/10.31550/1727-2378-2022-21-7-60-62
Abstract
Objective of the Paper: Demonstration of a clinical case of successful use of golimumab in a child with juvenile polyarthritis.
Key points. Juvenile polyarthritis is one of the most disabling clinical variants of juvenile idiopathic arthritis (JIA). In recent years, the range of medicines used in the therapy of JIA has significantly expanded. With the ineffectiveness of methotrexate, the appointment of genetically engineered biological drugs (GIBP) is shown, among which tumor necrosis factor α (TNF-α) inhibitors are most often used, one of which is golimumab.
Conclusion. To date, for the treatment of juvenile polyarthritis, there is golimumab in the arsenal of medicines, which is human monoclonal antibodies to TNF-α, which allows to achieve an inactive phase of the disease with the ineffectiveness of the use of other GIBP.
About the Authors
A. V. Aksenov
Federal State Budget Educational Institution of Higher Education the South-Ural State Medical University under the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
64 Vorovskoy`s Str., Chelyabinsk, 454000
E. A. Ivanovskaya
Municipal Autonomous Healthcare Institution Children's City Clinical Hospital No. 8
Russian Federation
Russian Federation
2 Druzhba Str., Chelyabinsk, 454047
References
1. Alekseeva E.I., Litvitsky P.F.; Baranov A.A., ed. Juvenile rheumatoid arthritis: etiology, pathogenesis, clinic, algorithms of diagnosis and treatment. A guide for doctors, teachers, and researchers. M.: Vedi; 2007. 368 p. (in Russian)
2. Aksenov A.V., Ivanovskaya Е.А. Successful use of tocilizumab in a child with systemic juvenile idiopathic arthritis. Doctor.Ru. 2021; 20(3): 70–72. (in Russian). DOI: 10.31550/1727-23782021-20-3-70-72
3. Aksenov A.V., Ivanovskaya Е.А. Successful use of adalimumab in children with juvenile idiopathic arthritis associated with uveitis. Doctor.Ru. 2021; 20(10): 73–75. (in Russian). DOI: 10.31550/1727-2378-2021-20-10-73-75
4. Denisova R.V., Alexeeva E.I., Dvoryakovskaya T.M., Soloshenko M.A. et al. Switching to a second TNF-α inhibitor in a patient with severe juvenile polyarthritis: a clinical case. Current Pediatrics. 2018; 17(4): 328–32. (in Russian). DOI: 10.15690/vsp.v17i4.1927
5. Kuchinskaya E.M., Kostik M.M., Snegireva L.S., Kalashnikova O.V. et al. Efficacy of golimumab in children with polyarticular juvenile idiopathic arthritis. Pediatrician. 2014; 5(4): 48–52. (in Russian). DOI: 10.17816/PED5448-52
6. Brunner H.I., Ruperto N., Tzaribachev N., Horneff G. et al. Subcutaneous golimumab children with active polyarticular-course juvenile idiopathic arthritis: results of a multicenter, double-blind, randomized-withdrawal trial. Ann. Rheum. Dis. 2018; 77(1): 21–9. DOI: 10.1136/annrheumdis-2016-210456
7. Frampton J.E. Golimumab: a review in inflammatory arthritis. BioDrugs. 2017; 31(3): 263–74. DOI: 10.1007/s40259-017-0217-6
8. Palmou-Fontana N., Calvo-Río V., Martín-Varillas J.L., Fernández Díaz C. et al. Golimumab in refractory uveitis associated to juvenile idiopathic arthritis: multicentre study of 7 cases and literature review. Clin. Exp. Rheumatol. 2018; 36(4): 652–7.
9. Lanz S., Seidel G., Skrabl-Baumgartner A. Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab. Pediatr. Rheumatol. Online J. 2021; 19(1): 132. DOI: 10.1186/s12969-021-00630-1
Review
For citations:
Aksenov A.V., Ivanovskaya E.A. Successful Use of Golimumab in a Child with Juvenile Polyarthritis. Title. 2022;21(7):60-62. (In Russ.) https://doi.org/10.31550/1727-2378-2022-21-7-60-62
Views:
6
Email this article 